BR112022005182A2 - Composto de amida heterocíclico, sal farmaceuticamente aceitável do mesmo, e método de preparação do mesmo e uso do mesmo - Google Patents

Composto de amida heterocíclico, sal farmaceuticamente aceitável do mesmo, e método de preparação do mesmo e uso do mesmo

Info

Publication number
BR112022005182A2
BR112022005182A2 BR112022005182A BR112022005182A BR112022005182A2 BR 112022005182 A2 BR112022005182 A2 BR 112022005182A2 BR 112022005182 A BR112022005182 A BR 112022005182A BR 112022005182 A BR112022005182 A BR 112022005182A BR 112022005182 A2 BR112022005182 A2 BR 112022005182A2
Authority
BR
Brazil
Prior art keywords
preparation
pharmaceutically acceptable
acceptable salt
amide compound
heterocyclic amide
Prior art date
Application number
BR112022005182A
Other languages
English (en)
Inventor
Huibin Zhang
Jian Ding
Jinpei Zhou
Meiyu Geng
Wenhu Duan
Xiaojun Yang
Xiyuan Wang
Yan Zhang
Yifei Yang
Zhaoxue Hu
Zuoquan Xie
Original Assignee
Univ China Pharma
Shanghai Inst Materia Medica Cas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ China Pharma, Shanghai Inst Materia Medica Cas filed Critical Univ China Pharma
Publication of BR112022005182A2 publication Critical patent/BR112022005182A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

composto de amida heterocíclico, sal farmaceuticamente aceitável do mesmo, e método de preparação do mesmo e uso do mesmo. são fornecidos um composto de amida heterocíclico de fórmula geral (i), um sal farmaceuticamente aceitável do mesmo e um método de preparação do mesmo, e o uso do composto na preparação de um fármaco para tratar doenças relacionadas à atividade de sting, na preparação de um adjuvante imunológico, e na preparação de um fármaco para ativar sting.
BR112022005182A 2019-09-19 2020-09-21 Composto de amida heterocíclico, sal farmaceuticamente aceitável do mesmo, e método de preparação do mesmo e uso do mesmo BR112022005182A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910891002.7A CN112521394A (zh) 2019-09-19 2019-09-19 杂环酰胺类化合物、其可药用的盐及其制备方法和用途
PCT/CN2020/116614 WO2021052501A1 (zh) 2019-09-19 2020-09-21 杂环酰胺类化合物、其可药用的盐及其制备方法和用途

Publications (1)

Publication Number Publication Date
BR112022005182A2 true BR112022005182A2 (pt) 2022-06-14

Family

ID=74883932

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022005182A BR112022005182A2 (pt) 2019-09-19 2020-09-21 Composto de amida heterocíclico, sal farmaceuticamente aceitável do mesmo, e método de preparação do mesmo e uso do mesmo

Country Status (10)

Country Link
US (1) US20220389025A1 (pt)
EP (1) EP4032890A1 (pt)
JP (1) JP2022549030A (pt)
KR (1) KR20220097388A (pt)
CN (2) CN112521394A (pt)
AU (1) AU2020348825B2 (pt)
BR (1) BR112022005182A2 (pt)
CA (1) CA3151776C (pt)
MX (1) MX2022003270A (pt)
WO (1) WO2021052501A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112521394A (zh) * 2019-09-19 2021-03-19 中国药科大学 杂环酰胺类化合物、其可药用的盐及其制备方法和用途
US20220388986A1 (en) * 2021-04-29 2022-12-08 Boehringer Ingelheim International Gmbh Heterocyclic compounds capable of activating sting
CN116332885A (zh) * 2023-02-13 2023-06-27 中国海洋大学 一种硝基杂环类sting激动剂及其制备方法和用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL295649A (en) * 2016-04-07 2022-10-01 Glaxosmithkline Ip Dev Ltd Heterocyclic amides are useful as protein modulators
EP3691640A1 (en) * 2017-10-05 2020-08-12 GlaxoSmithKline Intellectual Property Development Limited Methods for administering sting agonists
CN110016025B (zh) * 2018-01-08 2021-08-06 成都先导药物开发股份有限公司 一种免疫调节剂
WO2020028566A1 (en) * 2018-07-31 2020-02-06 Incyte Corporation Heteroaryl amide compounds as sting activators
CN112521394A (zh) * 2019-09-19 2021-03-19 中国药科大学 杂环酰胺类化合物、其可药用的盐及其制备方法和用途

Also Published As

Publication number Publication date
AU2020348825B2 (en) 2023-12-21
US20220389025A1 (en) 2022-12-08
AU2020348825A1 (en) 2022-04-28
MX2022003270A (es) 2022-07-04
CA3151776C (en) 2024-04-09
EP4032890A1 (en) 2022-07-27
CA3151776A1 (en) 2021-03-25
KR20220097388A (ko) 2022-07-07
CN114981273B (zh) 2024-03-01
JP2022549030A (ja) 2022-11-22
WO2021052501A1 (zh) 2021-03-25
CN114981273A (zh) 2022-08-30
CN112521394A (zh) 2021-03-19

Similar Documents

Publication Publication Date Title
BR112022005182A2 (pt) Composto de amida heterocíclico, sal farmaceuticamente aceitável do mesmo, e método de preparação do mesmo e uso do mesmo
CO2019008531A2 (es) Análogos de atazanavir (atv) para tratar infecciones por vih.
CL2022001625A1 (es) Derivados de pirazolilo útiles como agentes anti-cancerígenos
CL2020002866A1 (es) Compuestos de heteroaril tetracíclicos
BR112019007393A2 (pt) derivados 6,7,8,9-tetra-hidro-3h-pirazolo[4,3-f]isoquinolina úteis no tratamento de câncer
CO2017008862A2 (es) Composiciones farmacéuticas que comprenden n-(3,5-dimetoxifenil)-n’-(1-metiletil)-n-[3-(1-metil-1h-pirazol-4-il-quinoxalin-6-il]etano-1,2-diamina
BR112018070602A2 (pt) composto, composição farmacêutica, uso do composto, e, método para tratar uma doença ou distúrbio
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
BR112022010254A2 (pt) Composto heterocíclico contendo oxigênio representado pela fórmula i, método para preparar o composto heterocíclico contendo oxigênio, composto, composição farmacêutica e uso composto heterocíclico contendo oxigênio
AR095034A1 (es) El uso de los agonistas del receptor 2 del péptido formilo para el tratamiento de las enfermedades inflamatorias oculares
EA201792116A1 (ru) Ингибитор янус-киназы
BR112014003237A2 (pt) compostos de indazol, composições e métodos de uso
CO2021002977A2 (es) Dimetilaminoazetidinaminas como inhibidores de jak
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
MX2021012750A (es) Agonista de molécula pequeña del fxr y método de preparación para el mismo y uso del mismo.
CR20210213A (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
CO2021002976A2 (es) Amidas heterocíclicas de 5 a 7 miembros como inhibidores de jak
BR112014009190A2 (pt) formulação, uso de uma formulação, e, processo para a preparação de uma formulação
BR112017016817A2 (pt) derivados heterocíclicos formilados como inibidores de fgfr4
CO2020004669A2 (es) Derivados de bencimidazol y sus usos
MX2020003732A (es) Derivado de anillo fusionado como inhibidor del receptor a2a.
BR112021011325A2 (pt) Derivados de rapamicina
BR112021020297A2 (pt) Compostos de hexa-hidro-1h-pirazino[1,2-a]pirazina para o tratamento de doença autoimune
BR112022001568A2 (pt) Composto, método para preparação do composto, composição farmacêutica, e, uso do composto
BR112022012205A2 (pt) Compostos ativos para receptores nucleares

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]